{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:09:24Z","timestamp":1793966964332,"version":"4.8.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Globally, cancer cases are expected to significantly increase due to population growth and aging, reaching 29.9 million by 2040 (+49.5% since 2022) and 32.6 million by 2045 (+63%), with countries like Switzerland forecasting a 36.5% increase. Rare cancers, defined as less than six cases\/100,000 individuals\/year, account for 15-24% for recent nationwide studies but they have fewer treatment options and lower survival rates. Using the Geneva Cancer Registry, we analyzed rare cancer incidence and survival rates in adults from the canton of Geneva, Switzerland (2011\u20132020), with the aim of informing future research at local and national levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed adult patients diagnosed with invasive cancers (2011\u20132020) in Geneva using Geneva Cancer Registry data, which were annually updated. Rare cancers were defined according to RARECAREnet criteria (incidence less than six cases\/100,000 individuals\/year) and categorized into Tier 1 and Tier 2 entities based on clinical features. Crude and standardized incidence rates were calculated for both sexes using the 1976 European reference population, as well as age-specific rates for rare and common cancers. Five-year survival rates were estimated using the Kaplan\u2013Meier method. Survival differences between rare and common cancers were assessed using log-rank tests and Cox proportional hazards models adjusted for age and gender. Statistical analyses were performed using STATA software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 2011 and 2020, 31,233 invasive cancers were diagnosed in adults in Geneva, of which 4,296 cases (13.75%) were classified as rare based on aforementioned thresholds. While some rare Tier 1 cancers included common subtypes, most Tier 2 cancers (141 in total) were classified as rare, with significant gender disparities. Men had higher rare cancer rates such as epithelial hypopharynx, larynx, and liver tumors, while women had higher rates of squamous cell carcinoma of the anus. Rare neuroendocrine tumors, central nervous system tumors, and hematological malignancies, such as follicular B lymphoma and acute myeloid leukemia, were also prevalent among rare cancers. Rare cancers increase with age, but less so than common cancers. The 5-year survival rate for rare cancers was 58.4% when compared with 62.3% for common cancers, indicating a 15.7% higher risk of death for patients with these cancers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These findings highlight the critical challenges and requirements of targeted research and improving care strategies for rare cancers. Efforts combatting such cancers include European Reference Networks and the Swiss Sarcoma Network, which have improved access to care via collaborative efforts. In Switzerland, Molecular Tumor Boards have leveraged genomic knowledge to refine treatments and allow patient participation in clinical trials. Early referral to such boards for aggressive or treatment-limited cancers can streamline care and facilitate patient access to specialist centers. However, Switzerland requires more comprehensive data on the distribution of rare cancers in terms of age, gender, and region to improve management strategies at national levels.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1557424","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T04:10:28Z","timestamp":1743999028000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The burden of rare cancers among adults in the Canton of Geneva, Switzerland, from 2011 to 2020"],"prefix":"10.3389","volume":"15","author":[{"given":"Nathalie","family":"Bot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Amram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Rapiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v149.4","article-title":"Cancer statistics for the year 2020: An overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30445-X","article-title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet\u2014a population-based study","volume":"18","author":"Gatta","year":"2017","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v9.15","article-title":"Incidence and survival of rare cancers in the US and Europe","volume":"9","author":"Botta","year":"2020","journal-title":"Cancer Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2014.07.014","article-title":"The burden of rare cancer in Japan: Application of the RARECARE definition","volume":"38","author":"Tamaki","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21400","article-title":"The burden of rare cancers in the United States","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/0300891618821039","article-title":"ncidence of rare cancers in the city of S\u00e3o Paulo, Brazil","volume":"105","author":"Bustamante-Teixeira","year":"2019","journal-title":"Tumori J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"101721","DOI":"10.1016\/j.canep.2020.101721","article-title":"Rare cancers in Canada, 2006\u20132016: A population-based surveillance report and comparison of different methods for classifying rare cancers","volume":"67","author":"Walker","year":"2020","journal-title":"Cancer Epidemiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.03.001","article-title":"The gap between rare and common cancers still exists: Results from a population-based study in the Netherlands","volume":"167","author":"De Heus","year":"2022","journal-title":"Eur J Cancer"},{"key":"B9","article-title":"The burden of rare cancers in North America","volume":"50","author":"Hofer","year":"2023","journal-title":"J Regist Manage"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v152.8","article-title":"Geographical and spatial disparities in the incidence and survival of rare cancers in Australia","volume":"152","author":"Dasgupta","year":"2023","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejso.2017.08.018","article-title":"Epidemiology of rare cancers and inequalities in oncologic outcomes","volume":"45","author":"Gatta","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000666","article-title":"Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU)","volume":"5","author":"Casali","year":"2020","journal-title":"ESMO Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"115147","DOI":"10.1016\/j.ejca.2024.115147","article-title":"Incidence and survival of rare adult solid cancers in Europe (EUROCARE-6): A population-based study","volume":"214","author":"Trama","year":"2025","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1223164","article-title":"Global burden of esophageal cancer attributable to smoking: a systematic analysis for the Global Burden of Disease Study 2019","volume":"13","author":"Wu","year":"2023","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"102486","DOI":"10.1016\/j.canep.2023.102486","article-title":"Global trends in esophageal cancer mortality with predictions to 2025, and in incidence by histotype","volume":"87","author":"Santucci","year":"2023","journal-title":"Cancer Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1102236","article-title":"Descriptive epidemiology of the head and neck cancers in old patients","volume":"13","author":"Gatta","year":"2023","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.canep.2017.11.008","article-title":"Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013","volume":"52","author":"Schnegg-Kaufmann","year":"2018","journal-title":"Cancer Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001112","article-title":"Predicting the burden of cancer in Switzerland up to 2025","volume":"2","author":"Tr\u00e4chsel","year":"2022","journal-title":"PloS Glob Public Health"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Glob Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v154.7","article-title":"Cancer cases attributable to modifiable lifestyle risk factors in Switzerland between 2015 and 2019","volume":"154","author":"Jiang","year":"2024","journal-title":"Int J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"De Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"35458","DOI":"10.1002\/cncr.35458","article-title":"Burden of 30 cancers among men: Global statistics in 2022 and projections for 2050 using population-based estimates","volume":"130","author":"Bizuayehu","year":"2024","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.006","article-title":"Improving treatment results with reference centres for rare cancers: where do we stand","volume":"77","author":"Ray-Coquard","year":"2017","journal-title":"Eur J Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100861","DOI":"10.1016\/j.lanepe.2024.100861","article-title":"Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN","volume":"39","author":"Blay","year":"2024","journal-title":"Lancet Reg Health - Eur"},{"key":"B25","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1186\/s12913-020-05786-2","article-title":"Implementing a clinical cutting-edge and decision-making activity: an ethnographic teamwork approach to a molecular tumorboard","volume":"20","author":"Bot","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00824-4","article-title":"Molecular tumour boards \u2014 current and future considerations for precision oncology","volume":"20","author":"Tsimberidou","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CEJ.0000000000000842","article-title":"Global trends in anal cancer incidence and mortality","volume":"33","author":"Mignozzi","year":"2024","journal-title":"Eur J Cancer Prev"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1557424\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T04:10:32Z","timestamp":1743999032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1557424\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":27,"alternative-id":["10.3389\/fonc.2025.1557424"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1557424","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"article-number":"1557424"}}